OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

/PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"),...

Related Keywords

Philippines ,Hong Kong ,Malaysia ,Shenzhen ,Guangdong ,China ,United States ,Singapore ,Macau ,Taiwan ,Taipei ,T Ai Pei ,Calvin Tsai ,Tao Han ,Cytovance Biologics Inc ,European Medicines Agency ,Prnewswire Oncovent Co Ltd ,Shenzhen Qianhai Development Zone ,Orient Europharma Co Ltd ,Oncovent Co Ltd ,Taipei Exchange ,Shenzhen Hepalink Pharmaceutical Group Co Ltd ,Drug Administration ,Orphan Drug Designations ,Chief Executive Officer ,Asia Pacific ,Chief Business Officer ,Southeast Asia ,Mainland China ,Shenzhen Qianhai Development ,Shenzhen Hepalink Pharmaceutical Group Co ,Td ,